Nicotinamide Adenine Dinucleotide Phosphate Oxidase 2 Regulates LPS-Induced Inflammation and Alveolar Remodeling in the Developing Lung.

Heather Menden  
*Children's Mercy Hospital*

Sheng Xia  
*Children's Mercy Hospital*

Sherry M. Mabry  
*Children's Mercy Hospital*

Angels Navarro  
*Children's Mercy Hospital*

Michael F. Nyp  
*Children's Mercy Hospital*

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers

Recommended Citation  
Menden, Heather; Xia, Sheng; Mabry, Sherry M.; Navarro, Angels; Nyp, Michael F.; and Sampath, Venkatesh, "Nicotinamide Adenine Dinucleotide Phosphate Oxidase 2 Regulates LPS-Induced Inflammation and Alveolar Remodeling in the Developing Lung." (2016). *Manuscripts, Articles, Book Chapters and Other Papers*. 531.  
https://scholarlyexchange.childrensmercy.org/papers/531

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact library@cmh.edu.
Creator(s)
Heather Menden, Sheng Xia, Sherry M. Mabry, Angels Navarro, Michael F. Nyp, and Venkatesh Sampath

This article is available at SHARE @ Children's Mercy: https://scholarlyexchange.childrensmercy.org/papers/531
Nicotinamide Adenine Dinucleotide Phosphate Oxidase 2 Regulates LPS-Induced Inflammation and Alveolar Remodeling in the Developing Lung

Heather L. Menden, Sheng Xia, Sherry M. Mabry, Angels Navarro, Michael F. Nyp, and Venkatesh Sampath

Department of Pediatrics, Division of Neonatology, Children’s Mercy Hospital, Kansas City, Missouri

Abstract

In premature infants, sepsis is associated with alveolar simplification manifesting as bronchopulmonary dysplasia. The redox-dependent mechanisms underlying sepsis-induced inflammation and alveolar remodeling in the immature lung remain unclear. We developed a neonatal mouse model of sepsis-induced lung injury to investigate whether nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) regulates Toll-like receptor (TLR)-mediated inflammation and alveolar remodeling. Six-day-old NOX2+/− and NOX2−/− mice were injected with intraperitoneal LPS to induce sepsis. Lung inflammation and canonical TLR signaling were assessed 24 hours after LPS. Alveolar development was examined in 15-day-old mice after LPS on Day 6. The in vivo efficacy of a NOX2 inhibitor (NOX2-I) on NOX2 complex assembly and sepsis-induced lung inflammation were examined. Lung cytokine expression and neutrophil influx induced with sepsis in NOX2+/− mice was decreased by >50% in NOX2−/− mice. LPS-induced TLR4 signaling evident by inhibitor of NF-κB kinase-β and mitogen-activated protein kinase phosphorylation, and nuclear factor-κB/AP-1 translocation were attenuated in NOX2−/− mice. LPS increased matrix metalloproteinase 9 while decreasing elastin and keratinocyte growth factor levels in NOX2−/− mice. An LPS-induced increase in matrix metalloproteinase 9 and decrease in fibroblast growth factor 7 and elastin were not evident in NOX2−/− mice. An LPS-induced reduction in radial alveolar counts and increased mean linear intercepts were attenuated in NOX2−/− mice. LPS-induced NOX2 assembly evident by p67phox/gp91phox coimmunoprecipitation was disrupted with NOX2-I. NOX2-I also mitigated LPS-induced cytokine expression, TLR pathway signaling, and alveolar simplification. In a mouse model of neonatal sepsis, NOX2 regulates proinflammatory TLR signaling and alveolar remodeling induced by a single dose of LPS. Our results provide mechanistic insight into the regulation of sepsis-induced alveolar remodeling in the developing lung.

Keywords: nicotinamide adenine dinucleotide phosphate oxidase; sepsis; Toll-like receptor signaling; neonatal lung injury; bronchopulmonary dysplasia

Postnatal inflammation and tissue injury in the developing lung contribute to the disrupted alveolar development observed in premature infants with bronchopulmonary dysplasia (BPD) (1, 2). Risk factors associated with BPD, such as hyperoxia, barotrauma, and sepsis, trigger the production of reactive oxygen species (ROS) in the premature lung, which contributes to lung inflammation and matrix degradation (3–5). Multiple investigators have shown that markers of oxidant-mediated lung injury, such as 8-Oxo-2′-deoxyguanosine, oxidized surfactant phospholipids, F2-isoprostanes, and nitrotyrosine, are elevated in the bronchoalveolar lavage, serum, or urine of premature infants who subsequently develop BPD (4–7). Therapies to mitigate oxidant stress, such as recombinant superoxide dismutase and vitamin A, have been used in premature infants to decrease BPD, with limited success (8, 9). The preterm infant lung is particularly vulnerable to oxidant-mediated damage because lung antioxidant enzymes are...
Clinical Relevance

Our data provide mechanistic insight into sepsis-induced alveolar remodeling seen in premature infants with bronchopulmonary dysplasia. We demonstrate that nicotinamide adenine dinucleotide phosphate oxidase 2 regulates sepsis-induced inflammatory signaling and alveolar simplification in the developing lung. Use of a peptide inhibitor of nicotinamide adenine dinucleotide phosphate oxidase 2 during sepsis attenuates neonatal lung injury, suggesting a potential therapy for neonatal lung protection during sepsis.

developmentally regulated and not fully functional until term gestation (3, 6). Gram-negative bacterial sepsis is a common complication of preterm birth and is associated with an acute increase in ROS, lung inflammation, and the development of BPD (10, 11). The redox-dependent mechanisms regulating sepsis-induced inflammation and alveolar remodeling in the developing lung remain poorly understood and are the focus of this study.

During sepsis, bacterial cell-wall components such as LPS are recognized by the Toll-like receptor (TLR) family of innate immune receptors (12, 13). TLR-mediated bacterial recognition triggers complex signaling cascades, resulting in the activation of transcription factors nuclear factor-κB (NF-κB) and AP-1, which regulate inflammation and tissue injury in the lung (12). Activation of canonical TLR signaling increases intracellular ROS, and TLR-mediated inflammation has been shown in vitro to be regulated by the nicotinamide adenine dinucleotide phosphate oxidase (NOX) enzymes (14–17). The NOX family of oxidoreductases generates superoxide by one electron reduction of molecular oxygen using the reduced form of nicotinamide adenine dinucleotide phosphate as substrate. The seven NOX catalytic homologs differ in subunit composition, tissue distribution, and mode of activation (14, 16). Some NOX isoforms, such as NOX4, are constitutively active, whereas others are activated by cellular stress, hormones, cytokines, and bacterial ligands. NOX-derived ROS play a key role in homeostatic cellular signaling when compartmentalized and regulated (16, 18). However, pathological activation of NOX has been implicated in various disease processes such as ischemia-reperfusion, inflammation, hypertension, and cancer (14, 18). In the lung, NOX isoforms show cell-type–specific distribution and function and are found in endothelial cells, epithelial cells, fibroblasts, macrophages, and smooth muscle cells (18). Prior work in our laboratory demonstrated that nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) regulates LPS (TLR4 agonist)–mediated superoxide production and cytokine expression in fetal lung endothelial cells (15). To determine the in vivo relevance of NOX2 in proinflammatory TLR signaling, we used a mouse model to investigate whether NOX2 regulates sepsis-induced inflammation and alveolar remodeling in the developing lung.

Lung development in rodents is similar to that in premature infants because it progresses through the saccular and alveolar phase after birth (19). Traditionally, rodent models of BPD have used hyperoxia, antenatal endotoxin exposure, and mechanical ventilation to induce acute lung inflammation and alveolar remodeling in the immature lung (20, 21). Although it is accepted that systemic sepsis in the premature infant is a major risk factor for the development of BPD, the mechanisms by which sepsis-induced acute lung inflammation contributes to alveolar simplification in BPD remain poorly understood (11, 22, 23). To investigate the mechanisms underlying sepsis-induced inflammation and alveolar remodeling in the immature lung, we developed a model of neonatal sepsis using intraperitoneal LPS administration in 6-day-old mouse pups. We hypothesized that LPS-induced acute lung inflammation would remodel the developing lung and that NOX2 deficiency would protect against TLR-mediated lung injury. The results of this study suggest that NOX2 regulates sepsis-mediated lung inflammation and alveolar remodeling in the developing lung.

Materials and Methods

Animal Model

Care of mice before and during experimental procedures was performed in accordance with the policies of the Biomedical Resource Center, Medical College of Wisconsin, Laboratory Animal Research Core, University of Missouri–Kansas City, and the National Institutes of Health guidelines for the care and use of laboratory animals. All protocols had prior approval from the Medical College of Wisconsin Institutional Animal Care and Use Committee (AUA 3464) and the University of Missouri–Kansas City Institutional Animal Care and Use Committee (protocol number 1510). In experiments using the NOX2−/− animal model, timed breeding was used for animal comparisons. When the pups were at Day of Life 6, they received intraperitoneal injection of 1 mg/kg LPS (Sigma, St. Louis, MO), whereas the control mice received an equal volume injection of sterile saline solution. The pups were killed at 3, 6, 24, 96, or 196 hours after LPS administration using an intraperitoneal injection of a ketamine and xylazine mixture (100 mg/kg, 10 mg/kg, respectively). For experiments with the NOX2 inhibitor, gp91phox ds-tat (10 mg/kg, NOX2-inhibitor [NOX2-I]; Anaspec, Fremont, CA), and the p38 inhibitor SB202190 (10 mg/kg, p38-I; Abcam, Cambridge, MA), drugs were injected intraperitoneally 2 hours before intraperitoneal LPS injection. Lungs were harvested and used for experimentation as described below.

Hematoxylin and Eosin Staining to Assess Lung Development in Inflated Mouse Lungs

NOX2+/+ and NOX2−/− mouse pups were killed 196 hours after intraperitoneal injection of LPS or saline. The lungs were inflated using a fixed volume of formalin, as described previously by Parkinson and colleagues (24). Briefly, using a catheter, 300 μL of formalin fixative was used to inflate the lungs after the mice were killed. Precautions were taken to not over- or underinflate the lungs. The lungs were further fixed in formalin before being embedded in paraffin, cut into 4-μm sections onto slides, and stained with hematoxylin and eosin. The hematoxylin and eosin slides were scanned using a NanoZoomer slide scanner (Hamamatsu, Bridgewater, NJ), and the scanned
images were used at 40× for assessing radial alveolar count (25) and mean linear intercepts (26) following previously used protocols. At least four mice were used per condition in these experiments. For radial alveolar counts, quantification was performed by averaging 10 measurements per mouse.

For mean linear intercepts, quantifications were performed by averaging five high-power fields per mouse.

Figure 1. Lung cytokine expression and neutrophil influx after intraperitoneal (i.p.) LPS injection. Six-day-old nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) +/+ and NOX2 −/− pups were injected intraperitoneally with LPS or saline, and the lungs were harvested for real-time polymerase chain reaction and protein analysis at 24 and 96 hours (A–C). The left lung was used for immunofluorescence studies (D–E). (A) TNF-α, keratinocyte-derived cytokine (KC), and IL-1β mRNA expression quantified by real-time polymerase chain reaction after intraperitoneal LPS injections. *P < 0.01 (NOX2 +/+ control versus NOX2 +/+ i.p. LPS); #P < 0.02 (NOX2 +/+ i.p. LPS versus NOX2 −/− i.p. LPS) (n = 5). (B and C) Homogenized lung lysates after intraperitoneal injections of LPS in mouse pups were immunoblotted for intercellular adhesion molecule (ICAM-1) and IL-1β (B), with densitometric quantification of ICAM-1 and IL-1β shown graphically (C). *P < 0.01 (NOX2 +/+ control versus NOX2 +/+ i.p. LPS); #P < 0.02 (NOX2 +/+ i.p. LPS versus NOX2 −/− i.p. LPS) (n = 5). (D) Fluorescent microscope images depicting neutrophil influx by LY6G immunofluorescence staining. LY6G is shown in green and DAPI in blue. Images are shown at 20× magnification. (E) Graphical representation summarizing the data, with each mouse shown as an average of three representative images. *P < 0.05 (NOX2 +/+ control versus NOX2 +/+ i.p. LPS); #P = 0.01 (NOX2 +/+ i.p. LPS versus NOX2 −/− i.p. LPS) (n = 4). ANOVA with post hoc tests was used for analysis of data. HPF, high-powered field.
Treatment of Mice with gp91 ds-tat (NOX2-I) and SB202190 (p38-I) Chemical Injections

Two hours before intraperitoneal injection of LPS/saline, NOX2+/+ mouse pups were pretreated with intraperitoneal injection of 10 mg/kg of NOX2-I or p38-I or saline. Mice were killed 24 hours after the NOX2-I or p38-I injection, and harvested lung lobes were used for RNA (complementary DNA, real-time polymerase chain reaction) isolation and protein (Western blot) quantification, as described above. At least four mice were used per experimental condition.

Figure 2. Lung matrix metalloproteinase 9 (MMP-9), tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), elastin, and keratinocyte growth factor 7 expression after intraperitoneal LPS injection. Lungs were harvested from NOX2+/+ and NOX2-/- mouse pups injected with intraperitoneal LPS or saline after 24 or 96 hours for protein analysis. (A) Homogenized lung lysates were used to immunoblot MMP-9 and TIMP-1 at 24 hours; β-actin was used as a loading control. (B) MMP-9 quantification by densitometry is shown graphically. *P < 0.01 (NOX2+/+ control versus NOX2+/+ i.p. LPS); #P < 0.01 (NOX2+/+ i.p. LPS versus NOX2-/- i.p. LPS) (n ≥ 4). (C and D) Elastin (C) and fibroblast growth factor 7 (FGF7) (D) mRNA expression was quantified by real-time polymerase chain reaction 96 hours after intraperitoneal LPS injection. *P < 0.05 (NOX2+/+ control versus NOX2+/+ i.p. LPS); #P < 0.02 (NOX2+/+ i.p. LPS versus NOX2-/- i.p. LPS) (n ≥ 4). (E and F) Clarified lung lysates obtained 96 hours after LPS treatment in pups were blotted for FGF7 and elastin (E), with quantification by densitometry shown graphically (F). *P < 0.01 (NOX2+/+ control versus NOX2+/+ i.p. LPS); #P = 0.01 (NOX2+/+ i.p. LPS versus NOX2-/- i.p. LPS) (n ≥ 4). ANOVA with post hoc tests was used for analysis of data.
Supplement Section
Experimental detail for polymerase chain reaction, immunoblotting, phosphorylation, electrophoretic mobility shift assay, common precipitation, and immunofluorescence studies, as well as data analysis, are presented in the online supplement.

Results
NOX2 Regulates LPS-Mediated Acute Inflammation in the Developing Lung
We examined the effect of NOX2 deficiency on lung inflammation induced by intraperitoneal LPS injection in 6-day-old mice. Whole-lung TNF-α, keratinocyte-derived cytokine (KC), and IL-1β RNA expressions were increased more than fourfold at 24 and 96 hours after intraperitoneal LPS (Figure 1A). LPS-mediated increase in inflammatory gene expression was attenuated by ~50% in NOX2−/− mice (Figure 1A). Similarly, whole-lung protein expression of intercellular adhesion molecule (ICAM-1), which facilitates lung neutrophil influx, and IL-1β with systemic LPS were attenuated in NOX2−/− mice (Figures 1B and 1C). These data reveal that deficiency of NOX2 attenuates the pulmonary expression of proinflammatory cytokines induced with systemic LPS in 6-day-old mice. Neutrophil influx is a prominent feature of acute lung injury that contributes to lung inflammation and matrix degradation. To evaluate the effect of NOX2 deficiency on LPS-mediated lung neutrophil invasion, we performed immunofluorescence for Ly6G (a specific marker for neutrophils) in 4-μM lung sections 24 hours after intraperitoneal LPS. LPS-induced lung neutrophil influx at 24 hours was decreased by >60% in NOX2−/− mice (Figures 1D and 1E). These data demonstrate that the lung inflammation and neutrophil influx observed with systemic LPS is attenuated in NOX2−/− mice.

Effect of NOX2 Deficiency on Markers of Matrix Remodeling and Lung Growth
To evaluate the effect of sepsis on matrix degradation in the developing lung, we assessed protein levels of matrix metalloproteinase (TIMP) 1 (TIMP-1) after intraperitoneal LPS in 6-day-old mice. LPS administration induced lung MMP-9 levels by more than threefold at 24 hours (Figures 2A and 2B). Lung TIMP-1 expression was evident in control NOX2+/+ mice and remained unchanged after intraperitoneal LPS (Figure 2A). In NOX2−/− mice, LPS-induced lung MMP-9 expression was attenuated by >40% (Figures 2A and 2B) when compared with NOX2+/+ mice. Lung TIMP-1 expression in control NOX2−/− mice showed a nonsignificant increase when compared with NOX2+/+ mice but did not change with systemic LPS. These data suggest decreased MMP-9–dependent remodeling with sepsis in NOX2−/− mice.

To examine the effect of systemic LPS on pathways related to alveolar growth, we quantified Keratinocyte growth factor (fibroblast growth factor 7 [FGF7]), a lung growth factor, and elastin (27, 28). There were no significant changes in elastin and FGF7 RNA or protein 24 hours after LPS in NOX2−/− mice (data not shown), but both RNA and protein expression of elastin and FGF7 were reduced at 96 hours after LPS (Figures 2C–2E). The LPS-induced decrease in lung elastin RNA and protein expression was attenuated in NOX2−/− mice (Figures 2C–2E). Interestingly, systemic LPS appeared to induce FGF7 protein in NOX2−/− mice, resulting in significantly higher lung FGF7 levels when compared with NOX2+/+ mice treated with LPS. These data suggest that markers of lung growth are decreased with LPS in NOX2+/+ mice but are preserved in NOX2−/− mice.

Figure 3. Changes in inhibitor of NF-κB kinase-β ([IKK-β], p38, c-Jun N-terminal kinase [JNK], and inhibitor of NF-κB-α (IkB) phosphorylation after LPS injection: Six-day-old NOX2+/+ and NOX2−/− mouse pups were exposed to intraperitoneal injections of LPS or saline, and the lungs were harvested for Western blot. (A and B) Mouse lung lysates were used to assess IKK-β, p38, and JNK phosphorylation 24 hours after intraperitoneal LPS treatment by immunoblotting (A), and blots were quantified by densitometry (B). *P < 0.01 (NOX2+/+ control versus NOX2−/− i.p. LPS); #P < 0.01 (NOX2+/+ i.p. LPS versus NOX2−/− i.p. LPS) (n = 4). (C and D) Western blot (C) of mouse lung lysates showing changes in IkB-α phosphorylation 24 hours after intraperitoneal injection of LPS, and graphical representation (D) summarizing quantification by densitometry of IkB-α phosphorylation. *P < 0.001 (NOX2+/+ control versus NOX2−/− i.p. LPS); #P < 0.01 (NOX2+/+ i.p. LPS versus NOX2−/− i.p. LPS) (n = 4). ANOVA with post hoc tests was used for analysis of data.
examined the effect of NOX2 deficiency on LPS-mediated canonical TLR4 pathway signaling. Systemic LPS administration robustly increased inhibitor of NF-κB kinase-β (IKK-β) phosphorylation (Ser177/181) in the lungs of 6-day-old mice, indicating TLR pathway activation (Figures 3A and 3B). LPS-mediated IKK-β phosphorylation was inhibited by >50% in NOX2−/− mice (Figures 3A and 3B). Activation of the mitogen-activated protein kinase (MAPK) p38 and c-Jun N-terminal kinase (JNK) through phosphorylation is a key event that contributes to TLR-mediated inflammation. In NOX2−/− mice, intraperitoneal LPS-induced lung phosphorylation of p38 (Thr180/Tyr182) and JNK (Thr183/Tyr185) was evident at 24 hours (Figures 3A and 3B). p38 and JNK phosphorylation induced by systemic LPS were decreased in the lungs of NOX2−/− mice. To examine the role of p38 in enhancing NF-κB signaling in our model, we performed additional experiments with the specific p38 inhibitor (p38-I, SB202190, 10 mg/kg) (29, 30). Pretreatment with p38-I (2 hr) decreased LPS-induced p38 (Thr180/Tyr182) phosphorylation, NF-κB activation, and proinflammatory cytokine expression in NOX2+/+ mice (see online supplement).

In canonical TLR signaling, IKK-β phosphorylation mediates inhibitor of NF-κB-α (IκB-α) phosphorylation and ubiquitination, with subsequent release and nuclear translocation of IκB-bound NF-κB. To examine IκB-α cellular dynamics in our model, we examined IκB-α phosphorylation after systemic LPS. Lung IκB-α (Ser32) phosphorylation was increased with intraperitoneal LPS in NOX2+/+ mice at 20 hours (Figures 3C and 3D). NOX2 deficiency attenuated the IκB-α (Ser32) phosphorylation seen with systemic LPS treatment (Figures 3C and 3D). These results suggest that NOX2 regulates TLR pathway kinase activation and IκB-α phosphorylation during sepsis in the developing lung.

**LPS-Mediated Lung NF-κB and AP-1 Activation Is Attenuated in NOX2−/− Mice**

Activation of the transcription factors NF-κB and AP-1 in the lung during sepsis regulates proinflammatory cytokine expression (10). We therefore evaluated lung NF-κB and AP-1 activation in 6-day-old mice by quantifying nuclear translocation of the p65 and c-Jun subunits, respectively, using immunofluorescence. Twenty-four hours after systemic LPS, there was increased nuclear staining of p65 (Figures 4A and 4C) and c-Jun (Figures 4B and 4D) in lung sections. The number of lung cells with nuclear staining of p65 and c-Jun after LPS was attenuated in NOX2−/− mice (Figures 4A–4C). These data indicate that activation of NF-κB and AP-1 with sepsis is NOX2 dependent in the developing lung. To confirm NF-κB activation after LPS, we performed a shift assay for p65 in whole-lung nuclear homogenates. After LPS treatment, there was increased p65 in NOX2−/+ lung nuclear extracts, which was attenuated in NOX2−/− mice (Figures 4D and 4E).

![Figure 4](https://example.com/figure4.png)

**Figure 4.** Assessment of NF-κB (p65) and AP-1 (c-Jun) activation after intraperitoneal LPS injection. Lung sections (4 μM) obtained from 6-day-old NOX2−/+ and NOX2−/− mouse pups 24 hours after treatment with LPS or saline were used for immunofluorescence studies. Lung nuclear extracts obtained from pups 3 hours after treatment with LPS or saline were used for electrophoretic mobility shift assay. (A) Confocal microscope images depicting nuclear activation of p65 by immunofluorescence staining. p65 in the cytoplasm stains green and DAPI (nucleus) is blue; the light blue staining is activated p65 in the nucleus. Images were captured at 63× magnification. (B) Confocal microscope images depicting nuclear activation of c-Jun by immunofluorescence staining. c-Jun in the cytoplasm stains red and DAPI is blue; the magenta staining is activated c-Jun in the nucleus. Images are shown at 63× magnification. (C) Graphical representation summarizing data of nuclear p65 and c-Jun, with each mouse shown as an average of three representative images. *P < 0.01 (NOX2+/+ control versus NOX2−/+ i.p. LPS); **P < 0.01 (NOX2−/+ i.p. LPS versus NOX2−/− i.p. LPS) (n = 4). (D and E) Lung nuclear extracts were used with an electrophoretic mobility shift assay using NF-κB (p65) binding oligo. A gel-shifted band appears in LPS-treated NOX2−/+ lungs (D and E), but not NOX2−/− lungs (E). There was no band present in the negative control (NC), which had a combination of hot and cold probes. C, control.
Effect of NOX2 ds-tat on LPS-Induced Lung Inflammation and TLR Signaling

To investigate the therapeutic potential of NOX2 activity modulation in sepsis-induced lung inflammation, we tested intraperitoneal gp91phox ds-tat (NOX2-I, 10 mg/kg), a synthetic peptide that binds to gp91phox and inhibits NOX2 assembly in our model (31). First, we examined the assembly of NOX2 complex in the lung by immunoprecipitating gp91phox and probing for the cytosolic subunit p67phox. In control NOX2+/− mice, p67phox was not bound to gp91phox. LPS treatment induced the association of p67phox with gp91phox in whole-lung homogenates, suggesting activation of NOX2 complex assembly (Figure 5A). LPS-induced lung NOX2 assembly was inhibited in mice pretreated (2 hr) with intraperitoneal NOX2-I (Figures 5A and 5B). Consistent with inhibition of lung NOX2 complex formation with NOX2-I, LPS-induced lung cytokine RNA expression and ICAM-1 expression at 24 hours were attenuated in mice pretreated with intraperitoneal NOX2-I (Figures 5C–5E). These data show that NOX2 inhibition ameliorates LPS-induced inflammation in the developing lung.

We next examined whether NOX2-I inhibits proinflammatory TLR signaling in 6-day-old mice. LPS-induced IKK-β (Ser177/181), p38 (Thr180/Tyr182), and JNK (Thr183/Tyr185) phosphorylation in the lung was attenuated in mice pretreated with intraperitoneal NOX2-I (Figures 6A and 6B). Similarly, LPS-induced lung NF-κB activation examined by quantifying p65 nuclear translocation 24 hours after LPS was also decreased in mice pretreated with NOX2-I (Figures 6C and 6D). These data show that NOX2-I mitigates LPS-induced inflammation in the developing lung by modulating proinflammatory TLR signaling.

Effect of NOX2 Deficiency on LPS-Mediated Pulmonary Alveolar Remodeling

To evaluate the impact of systemic LPS on lung development, we assessed mean radial alveolar counts and mean linear intercepts on Postnatal Day 15 after administering intraperitoneal LPS on Postnatal Day 6. Compared with control mice, LPS-treated mice had a 50% decrease in mean radial alveolar counts and a 40% increase in mean linear intercepts (Figure 7). These data are supportive of disrupted lung development with LPS treatment. Because NOX2 deficiency attenuates lung inflammation after intraperitoneal LPS in our model, we investigated whether less lung inflammation in NOX2−/− mice translated into improved lung development. In NOX2−/− mice treated with LPS, mean radial alveolar counts were significantly higher, whereas mean linear intercepts were lower when compared with NOX2+/− mice (Figure 7). To investigate the therapeutic potential of inhibiting NOX2 in preventing sepsis-induced alveolar remodeling, we tested NOX2-I. NOX2−/− mice pretreated with NOX2-I had less alveolar simplification when compared with NOX2+/− mice after LPS treatment (Figure 7). These data suggest that NOX2 deficiency protects against LPS-mediated alveolar remodeling in the developing lung.

Discussion

The key molecular players that regulate sepsis-induced inflammation and alveolar remodeling in the developing lung remain poorly understood. The results of this study

Menden, Xia, Mabry, et al.: NOX2 Regulates Lung Inflammation and Simplification

773
establish that NOX2 regulates lung inflammation in response to systemic LPS in neonatal mice. Using both genetic and peptide-inhibitor strategies, we show that TLR signaling through the IKK-β/NF-κB and MAPK/AP-1 pathways in sepsis is regulated by NOX2. Sepsis-induced cytokine expression, neutrophil influx, and alterations in markers of lung growth/matrix remodeling were attenuated with NOX2 deficiency. We also show that sepsis-induced inflammation in late saccular/early alveolar lung can disrupt lung development, resulting in alveolar simplification akin to that observed in premature infants who develop BPD in relation to systemic sepsis. NOX2 inhibition or deficiency attenuated sepsis-induced alveolar remodeling in the immature lung. Although our results provide novel insights into the mechanisms underlying sepsis-induced alveolar remodeling in the developing lung, lack of cell-type–specific data is a limitation of the study.

An acute increase in lung cytokine levels and neutrophil influx have been reported in infants or adults with sepsis-induced acute lung injury (10, 18, 32). In our neonatal model of sepsis induced by intraperitoneal LPS, we observed an acute increase in lung expression of cytokines TNF-α, KC (equivalent to human IL-8), IL-1β, and ICAM-1, similar to studies of sepsis-induced lung injury in adult rodent models. To determine whether NOX2-dependent signaling contributes to inflammation in the developing lung, we performed matched experiments in NOX2−/− mice lacking the catalytic subunit gp91phox. Sepsis-induced lung cytokine expression was attenuated by >50% in NOX2−/− mice. These data are consistent with the findings of Imai and colleagues (33), who showed that a deficiency in pathogen-induced oxidative stress protects against acute lung inflammation. Imai and colleagues (33) demonstrated that mice lacking p47phox (cytosolic subunit of NOX2) or TLR4 are protected against lung injury induced by H5N1 pulmonary infection. Although our model involved systemic LPS (a TLR4 ligand) injection, our data also suggest that TLR-mediated lung inflammation is NOX2 dependent in neonatal mice. In contrast with our data, the findings of Gao and colleagues (32), who used a model of Escherichia coli sepsis, showed that lung bacterial clearance decreased in parallel with increased lung polymorphonuclear sequestration in mice lacking gp91phox or p47phox. Their data suggest that lack of NOX2 potentiates neutrophil influx in sepsis, in contrast with our data showing decreased neutrophil influx in NOX2−/− mice. However, Gao and colleagues (32) did find that sepsis-induced microvascular permeability and injury were decreased in NOX2−/− mice. Differences in our results could potentially be explained by a cell-type–specific function of NOX2 and the use of live bacteria versus a selective TLR4 ligand in our study. In the study by Gao and colleagues (32), lack of neutrophilic NOX2 function inhibited bacterial clearance, which triggered macrophage inflammatory protein 2–induced neutrophil influx. However, decreased NOX2 function in endothelial cells protected against microvascular injury and ICAM-1–mediated lung neutrophil influx. Interestingly, Gao and colleagues (32) did find, as in our study, that lung ICAM-1

**Figure 6.** Effect of gp91phox ds-tat (NOX2−/−) on lung Toll-like receptor pathway signaling and NF-κB activation after intraperitoneal LPS injection. Six-day-old NOX2−/− mouse pups were pretreated with intraperitoneal NOX2−/− (10 mg/kg) 2 hours before intraperitoneal injection of LPS or saline. (A and B) Homogenized lung lysates obtained 24 hours after intraperitoneal LPS injection were used to assess the phosphorylation of IKK-β, p38, and JNK by immunoblotting (A), and blots were quantified by densitometry (B). *P < 0.01 (control versus i.p. LPS); †P < 0.01 (i.p. LPS versus NOX2−/− i.p. LPS) (n = 4). (C and D) Confocal microscope images depicting nuclear activation of NF-κB (p65) by immunostaining. Nuclear p65 staining represents cells with p65 in the nucleus, suggesting NF-κB activation. (D) Graph summarizing nuclear NF-κB (p65) data, with each mouse shown as an average of three representative images. *P < 0.01 (NOX2−/− control versus NOX2−/− i.p. LPS); †P < 0.01 (NOX2−/− i.p. LPS versus NOX2−/− i.p. LPS). Images were captured at 63× magnification (n = 4). ANOVA with post hoc tests was used for analysis.
Fig 7. Changes in lung morphometry after LPS injection. NOX2<sup>+/+</sup>, NOX2<sup>−/−</sup>, and NOX2<sup>+/−</sup> pups pretreated with intraperitoneal NOX2-I were injected with LPS or saline intraperitoneally on Day of Life 6, and lungs were inflation fixed for morphometric analysis. Mouse lung sections (4 μm) were stained with hematoxylin and eosin, and pictures were scanned for analysis (A). Scale bars: 100 μm. (B) Radial alveolar counts were performed by averaging 10 measurements per mouse. Graphical representation summarizing radial alveolar counts is shown. *P < 0.01 (NOX2<sup>+/+</sup> control versus NOX2<sup>+/−</sup> i.p. LPS); #P < 0.01 (NOX2<sup>+/−</sup> i.p. LPS versus NOX2<sup>−/−</sup> + i.p. LPS); ##P < 0.01 (NOX2<sup>+/−</sup> i.p. LPS versus NOX2<sup>−/−</sup> + i.p. LPS + NOX2-I) (n = 4). (C) Mean linear intercepts were performed by averaging five areas per mouse. Graphical representation summarizing mean linear intercepts is shown. *P < 0.01 (NOX2<sup>+/−</sup> control versus NOX2<sup>−/−</sup> i.p. LPS); #P < 0.01 (NOX2<sup>+/−</sup> i.p. LPS versus NOX2<sup>−/−</sup> + i.p. LPS); ##P < 0.01 (NOX2<sup>+/−</sup> i.p. LPS versus NOX2<sup>+/−</sup> + i.p. LPS + NOX2-I). Differences between NOX2<sup>+/−</sup> mice and NOX2<sup>−/−</sup> mice, as well as between NOX2<sup>+/−</sup> mice and NOX2<sup>+/−</sup> treated with NOX2-I, were analyzed separately using ANOVA with post hoc tests.
activation of transcription factors. NF-κB and AP-1 activation in sepsis was also evident in NOX2−/− mouse pups but it was significantly attenuated compared with NOX2+/+ mice. Although consistent with the findings of studies reporting ROS-dependent activation of NF-κB and AP-1 during sepsis-induced lung injury, our data suggest that NOX2 regulates LPS-mediated activation of redox-sensitive transcription factors in the developing lung (38–42). ROS generated from the mitochondrial transport chain, uncoupled endothelial nitric oxide synthase, and xanthine oxidase have been reported to propagate lung inflammation during sepsis (10, 43). NOX2-derived superoxide can also interact with catalytic products of the above enzymes to form highly reactive ROS such as peroxynitrite, which contribute to inflammation and tissue damage (10, 14). Although our data confirm the role of NOX2 in lung inflammation and alveolar remodeling, future studies to dissect the cross-talk between NOX2 and other redox pathways in our model are planned. We used whole-lung tissue for our experiments and therefore are not able to discern the cell-type-specific role of NOX2 in sepsis-induced lung inflammation. Because NOX2 is expressed in multiple lung cell types, we sought to investigate the global effect of NOX2 loss or suppression (gp91phox ds-tat) on LPS-induced inflammation in the developing lung (18). Future studies will investigate the differential role of cell-type-specific NOX2 function in sepsis. These data provide new insights into the mechanisms by which NOX2 regulates proinflammatory TLR signaling during sepsis in vivo.

Animal models to study the effects of noxious stimuli on lung development in BPD have focused on prenatal endotoxin exposure, postnatal hyperoxia or hypoxia, and mechanical ventilation (20, 21, 44). To the best of our knowledge, this is one of the first studies to examine the mechanisms underlying systemic sepsis-induced lung remodeling, which is observed in premature infants who develop “new BPD” without significant exposure to hyperoxia or ventilation (2). In our model, LPS-induced inflammation in the developing lung results in increased mean linear intercepts and decreased radial alveolar counts, suggesting that systemic sepsis alone causes alveolar simplification (1). Our data are in agreement with studies showing that intraamniotic endotoxin or neonatal intratracheal LPS exposures remodel the lung in rodents (45, 46), and suggest that activation of proinflammatory TLR signaling in the developing lung disrupts lung morphogenesis. Consistent with this postulate, NOX2−/− mice reveal decreased TLR-mediated lung inflammation and less alveolar simplification when compared with NOX2+/+ mice after sepsis. Although lung matrix remodeling is a complex process in the developing lung, activation of MMPs in the setting of decreased levels of TIMP is a known cause of inflammation-dependent lung matrix degradation (47). We observed that lung MMP-9 increases levels with systemic LPS, with no change in TIMP-1 expression. Lung MMP-9 induction in sepsis was decreased in NOX2−/− mice, suggesting decreased alveolar destruction. Previous studies in premature infants have shown that increased MMP-9 or MMP-9/TIMP-1 levels are associated with increased risk of BPD (48, 49). Furthermore, in sepsis-related acute respiratory distress syndrome, imbalances in MMPs and their inhibitors, TIMPs, have been reported in animal studies as well as in humans (47, 50). To examine the relationship between sepsis-mediated alveolar simplification and pathways related to lung growth, we quantified FGF7 (keratinocyte growth factor) and elastin expression in our model (27, 28, 51). We found that LPS treatment decreased FGF7 and elastin expression in the lung, and that NOX2 deficiency attenuated this response. Differences in lung MMP-9 and FGF7 levels observed with sepsis might be potential mechanisms contributing to attenuated alveolar remodeling in NOX2−/− mice. Further research is required to understand the mechanisms underlying increased MMP-9 in sepsis and the function of NOX2 in regulating MMP-9 and TIMP-1 in the developing lung.

To test the potential therapeutic benefits of NOX2 inhibition on sepsis-induced lung inflammation, we performed experiments with gp91phox ds-tat, a cell-permeable peptide that inhibits NOX2 activation by disrupting assembly of the active NOX2 complex (31, 52). Data showing coimmunoprecipitation of p67phox with gp91phox 6 hours after systemic LPS demonstrate that an active NOX2 complex is assembled in the lung during sepsis. Pretreatment with gp91phox ds-tat decreased coimmunoprecipitation of p67phox with gp91phox, confirming inhibition of lung NOX2 activation with the peptide inhibitor. Although the mechanism and specificity of gp91phox ds-tat has been elucidated in vitro, these original data validate its function in vivo (31, 53). Consistent with the inhibition of lung NOX2 assembly by gp91phox ds-tat, sepsis-induced cytokine and ICAM-1 expression were attenuated in mice treated with the peptide inhibitor. Furthermore, similar to our data obtained in NOX2−/− mice, gp91phox ds-tat decreased LPS-induced lung TLR pathway activation, as evidenced by decreased IKK-β/MAPK phosphorylation and NF-κB activation. Inhibition of proinflammatory TLR signaling with NOX2-1 preserved lung architecture, as evidenced by increased radial alveolar counts and decreased mean linear intercepts. These data strongly suggest that NOX2 inhibition during neonatal sepsis attenuates lung inflammation, tissue damage, and alveolar remodeling. Although the use of gp91phox ds-tat in an animal model of sepsis is new, these data are consistent with other reports that indicate NOX2-mediated injury in hypertension, diabetes, and inflammasome activation is inhibited with gp91phox ds-tat (31, 54, 55). We used gp91phox ds-tat before intraperitoneal LPS injection to generate proof-of-principle data as a potential therapeutic agent in sepsis. Future studies must examine whether gp91phox ds-tat decreases lung inflammation if administered after LPS injection, and whether it is effective in the phase of sepsis caused by live bacteria.

Conclusions

In summary, we developed a model of systemic LPS injection in neonatal mice to investigate the mechanisms by which postnatal sepsis contributes to disrupted alveolar development. We demonstrated that systemic LPS administration activates canonical TLR signaling in the developing lung, which disrupts alveolar development, resulting in a phenotype similar to the alveolar simplification observed in premature infants with BPD. Using both genetic and inhibitor studies, we showed that NOX2 regulates proinflammatory TLR pathway activation in sepsis and that NOX2 deficiency or inhibition attenuates sepsis-induced lung injury and alveolar remodeling.
References


